Middle East Respiratory Syndrome (MERS) Therapeutics Pipeline Analysis

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Coronaviruses are a type of viruses that affect the respiratory tract of mammals, including humans. Human coronaviruses usually cause mild to moderate cold-like illnesses. However, MERS-CoV is different from any other coronavirus previously found in people.

Request to Get Sample Pages at: https://www.pharmaproff.com/request-sample/1066

The infected patients may have mild symptoms or no symptoms at all, but most people infected with MERS-CoV develop severe respiratory illness, fever, cough, and shortness of breath. Some patients have reported to have gastrointestinal symptoms like diarrhea and nausea/vomiting; and kidney failure. MERS-CoV is known to spread from an infected person to others through respiratory secretions like coughing. However, the precise way in which this virus spreads has not been well understood yet. Some of the companies having drugs in the MERS syndrome pipeline includes Atriva Therapeutics GmbH and Inovio Pharmaceuticals Inc. are known to be involved in MERS pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1066

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.